Clinical Trials Browser

INDUSTRY × ibrutinib × Genitourinary × Clear all

NCT02599324 2023-11-18

Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

Phase 1/2 Completed

263 enrolled 34 charts

Carcinoma, Renal Cell